The coronavirus pandemic remains a major public health burden with multisystem disease manifestations. There has been an ongoing global effort to better understand the unique cardiovascular manifestations of this disease and its associated arrhythmias. In this review, we summarize the current data on incidence and outcomes of arrhythmias in the acute and convalescent period, possible pathophysiologic mechanisms, and medical management. Sinus bradycardia—reported in multiple observational studies in the acute infectious period—stands out as an unexpected inflammatory response. Atrial fibrillation has been noted as the most common pathologic arrhythmia and has been shown to be a poor prognostic marker in multiple cohorts. In the convalescent period, long-term complications such as postural orthostatic tachycardia syndrome and inappropriate sinus tachycardia have been described.
INTRODUCTION

Coronavirus disease 2019 (COVID-19) has had a profound impact on global health for the last 2 years. Medical providers have faced numerous challenges in understanding the pathophysiology, complications, and management of the disease and in providing patient care while minimizing exposure. Cardiac manifestations of this disease have taken on many forms, including myocardial infarction, viral myocarditis, and arrhythmias. COVID-19–related arrhythmias were initially described in data from Wuhan, China, published in February 2020. In their study population of 138 hospitalized COVID-19 patients, arrhythmias occurred at a rate of 16.7% in the overall population and 44.4% in those in the intensive care unit. Since that initial data, multiple centers have sought to better clarify the types of arrhythmias associated with COVID-19 as well as their prognostic implications.

In this review, we aim to focus on the incidence, pathophysiology, and management of cardiac arrhythmias with COVID-19 infection in the acute and convalescent period.

ARRHYTHMIA IN ACUTE COVID-19 INFECTION

PATHOPHYSIOLOGY OF COVID-19

COVID-19 infection has been hypothesized to progress over multiple stages: an initial viral phase with viral constitutional symptoms, a secondary infection stage with viral entry into cells and replication primarily in type II pneumocytes leading to respiratory failure and acute respiratory distress syndrome (ARDS), and sometimes a more severe stage of multisystem failure with inflammation due to a cytokine storm. The inflammatory cytokines are known to cause arrhythmias due to sympathetic overactivation. Multiple cytokines including interleukin-6 (IL-6) and tumor necrosis factor-α can directly modify expression and function of cardiac potassium and calcium channels affecting the myocyte action potential, specifically in genetically predisposed individuals.

Acute respiratory failure and ARDS following pulmonary infiltration from COVID-19 leads to hypoxia. The association between acute hypoxia and cardiac arrhythmias is well known and has been studied prior to the COVID-19 pandemic. Hypoxia can modify the function of L-type calcium channels affecting the plateau phase of action potential. Additionally, hypoxia eventually leads to anaerobic metabolism, which reduces intracellular pH and affects action potential duration. This has been shown to cause cardiac conduction tissue remodeling and anisotropy due to the effects on cardiac gap junction proteins connexin 40 and connexin 43, resulting in atrial and ventricular arrhythmia.

Direct myocardial injury has been noted in a significant number of patients with COVID-19. Markers for cardiac injury and inflammation—including NT-proBNP, cardiac troponin I, and high-sensitivity C-reactive protein—have been significantly associated with severity of disease and indicate its potential for myocarditis. Acute viral myocarditis can cause direct cytotoxic remodeling of cardiac conduction tissue, microvascular ischemia, gap junction dysfunction, and ion-channel dysregulation, all increasing the risk for arrhythmias. Post-inflammatory myocardial fibrosis and scar have also been observed, which can increase the risk for re-entrant arrhythmias.

Electrolyte abnormalities and fluid imbalance related to acute kidney injury and gastrointestinal symptoms have also been noted in a significant number of patients hospitalized for COVID-19. Significant derangements in potassium, magnesium, calcium, and phosphorus can all increase risk for new arrhythmia and exacerbate preexisting conduction disease. Additionally, early COVID-19 therapies such as hydroxychloroquine and azithromycin were known to carry an increased risk for arrhythmias. These medications can inhibit hERG potassium channels, which are responsible for the rapid delayed rectifier current (I\(_{\text{Kr}}\)). The resultant prolongation of the cardiac action potential and increased early afterdepolarization leads to a prolonged QT interval and increased risk for torsade de pointes (TdP).

Inflammation and hypoxemia are common mechanisms of cardiac arrhythmia but can be exacerbated by drugs or electrolyte imbalances that prolong QT. Some of these patients developed sinus bradycardia, which also plays a role in prolonged QT. This bradycardia is unexpected and different from the sinus tachycardia common in other patients with respiratory failure and hypoxemia. Although the exact mechanism of the sinus bradycardia is unclear, the pacemaker cell dysfunction at the sinus node is evident.

The sum of these various metabolic changes affects an individual’s risk for arrhythmia during the acute infectious period (Figure 1).

ARRHYTHMOGENESIS OF MEDICAL THERAPY IN ACUTE COVID-19 INFECTION

Throughout the pandemic, a variety of therapies have been evaluated for their antiviral and/or anti-inflammatory effects or their efficacy in improving ARDS. However, many of these medications have been associated with an increased risk of arrhythmias. For example, the combination of...
hydroxychloroquine and azithromycin was shown to have an antiviral effect in a small study from France, and many providers used this early during the pandemic. Although it was granted emergency use authorization by the US Food and Drug Administration (FDA), this therapy was later revoked after larger randomized studies demonstrated no significant effect on mortality or clinical status for patients with COVID-19.

The main concern regarding arrhythmia is the QT prolongation effect and increased risk for TdP when taking hydroxychloroquine/azithromycin. A few cohort studies showed relatively little risk, with only small-to-moderate increases to QT interval after a short course of treatment with hydroxychloroquine +/- azithromycin. In a systematic review by Jankelson et al. of 1,515 COVID-19 patients treated with hydroxychloroquine or chloroquine with and without azithromycin, about 10% of patients developed clinically significant QT prolongation (QTc > 500 ms or increase > 60 ms). They also found two documented cases of ventricular arrhythmia in patients with severe COVID-19 treated with high-dose chloroquine. Due to this risk, hydroxychloroquine and azithromycin are no longer recommended in the routine treatment of COVID-19 patients.

Combination lopinavir-ritonavir was also used early on as an experimental treatment for COVID-19 due to some evidence of efficacy during the previous outbreaks of SARS-CoV in 2003 and MERS-CoV in 2012. However, previous use in patients with the human immunodeficiency virus demonstrated significant bradyarrhythmia as well as tachy-brady syndrome. In a cohort of 41 COVID-19 patients with critical illness treated in ICUs, 22% developed significant bradycardia with one case of third-degree atrioventricular block. These bradyarrhythmia episodes were attributed to the therapy since they started within 48 hours of initiation and resolved after discontinuation, with no cases among patients who did not receive the therapy. Lopinavir-ritonavir is no longer recommended for COVID-19 patients.
after further studies failed to show significant benefit to mortality or clinical status.28

Remdesivir has now become the primary antiviral therapy used for COVID-19 after demonstrating modest benefit in improving clinical course and shortening time to recovery in moderate to severe cases.29,30 However, multiple case reports of bradycardia resulting from remdesivir treatment have been reported.31-33 In a review of the World Health Organization Case Safety Reports database, Toufchia et al. compared the incidence of bradycardia among COVID-19 patients treated with remdesivir versus those treated with hydroxychloroquine, lopinavir-ritonavir, tocilizumab, or glucocorticoids and found a significantly increased risk of severe bradycardia and of reporting bradycardia (OR 1.65; 95% CI, 1.23-2.22) in those treated with remdesivir.34

There are many other additional adjunct therapies being used in the management of COVID-19 patients. Tocilizumab, a potent IL-6 receptor antagonist, has had mixed results in showing benefit to hospitalized patients but is commonly used for its anti-inflammatory effects.35,36 Prior studies have shown an actual arrhythmic benefit with this medication because it tends to shorten the QTc interval, indicating that it may have a protective effect when other QTc-prolonging medications are being used.9,37 High-dose corticosteroids are also frequently used given their demonstrated mortality benefit in critically ill COVID-19 patients and lower relative cost.38 Generally, corticosteroids don’t confer an increased risk of malignant arrhythmias, but they were previously shown to increase the risk for the development of atrial fibrillation.39 For critically ill COVID-19 patients with ARDS, heavy sedation is a mainstay of therapy and involves use of paralytics and sedatives such as propofol and dexmedetomidine. Propofol, which is a known cardiac depressant, carries both anti-arrhythmic and proarrhythmic properties due to its ability to suppress both sympathetic and parasympathetic tone while also preserving gap junctions in ischemia.40 Dexmedetomidine, a selective alpha-2 receptor agonist, is commonly used in patients with high sedation requirements; it carries a known risk of bradycardia but may have some degree of favorable QTc shortening.41-43

**INCIDENCE OF CARDIAC ARRHYTHMIAS IN ACUTE INFECTION OF COVID-19**

Multiple centers have been actively engaged in efforts to better clarify the burden of arrhythmias associated with COVID-19. The ACovid (Arrhythmias in hospitalized patients with COVID-19) study in Denmark recruited individuals over age 18 admitted with COVID-19 to one of six nearby hospitals in Copenhagen and prospectively monitored them for various arrhythmias. Out of only 54 patients, they found 9 events of cardiac arrest (one with TdP), 25 incident atrial fibrillation (AF) events, 9 bradyarrhythmias, and 10 nonsustained ventricular tachycardia (NSVT) events.41 In California, Cho et al. reviewed the telemetry data of 143 COVID-19 patients at Cedars-Sinai hospital and found that 39.9% had sinus tachycardia. Other common arrhythmias included premature ventricular contractions (PVCs) at 28.7%, NSVT at 15.4%, AF at 11.9%, and supraventricular tachycardia (SVT) at 5.6%. Malignant arrhythmias such as ventricular tachycardia/ventricular fibrillation (VT/VF) and atrioventricular (AV) block were rare, occurring in 0.7% to 1.4%. The only significant difference they found between survivors and nonsurvivors was a higher frequency (58.3%) of sinus tachycardia in nonsurvivors.42

A larger data set from Bhatla et al. at the University of Pennsylvania retrospectively evaluated 700 patients admitted between March 2020 and May 2020 and found arrhythmic events to be quite rare. They found nine cardiac arrests, six of which were pulseless electrical activity (PEA), one asystole, and one TdP. There were 25 incident AF events, 9 significant bradyarrhythmias, and 10 events of NSVT. There were no noted cases of AV block or sustained VT/VF. ICU status was found to be independently associated with incident AF in multivariate analysis (OR 1.05; 95% CI, 1.02-1.09). Heart failure was associated with bradyarrhythmias (OR 9.75; 95% CI, 1.95-48.65).44 Table 1 summarizes incidence data and various management strategies.
occurred in 8% of 1,029 patients admitted with COVID-19, and within that group, 8% had SVTs, 5 cases had long RP tachycardia, and 2 had short RP tachycardia. The cases of long RP tachycardia were thought to most likely represent focal atrial tachycardia.

**VENTRICULAR ARRHYTHMIAS**

Ventricular arrhythmias including VT/VF, NSVT, and PVCs have been reported to occur quite rarely in most study populations, although Cho et al. found PVCs and NSVT to be quite common within their cohort. Abrams et al. from Columbia University published a case series of 5 critically ill COVID patients who had VT/VF, three of which were refractory to amiodarone and defibrillation. Although these patients had risk factors for cardiovascular disease such as obesity, hypertension, and diabetes, none had any history of heart failure, left ventricular dysfunction, or evidence of infarct on electrocardiogram. The authors theorized that these VT/VF arrests were more likely secondary to iatrogenic factors such as permissive hypercapnia, electrolyte imbalances, and COVID-19–directed therapies. Shao et al. reviewed cardiac arrest data for COVID infections in Wuhan between January and February 2020 and found that 5.9% of cardiac arrests were due to a shockable rhythm such as VT/VF.

**BRADYARRHYTHMIAS**

Bradyarrhythmias such as sinus bradycardia associated with COVID-19 have been well described, yet cases of individuals needing temporary or permanent pacemaker implantation are rare. Kumar et al. looked specifically at the occurrence of absolute bradycardia (HR < 60) and profound bradycardia (HR < 50) associated with 1,053 admitted COVID-19 patients. Excluding patients on AV nodal blockers or with end of life bradycardia, the authors found that absolute bradycardia occurred in 24.9% of COVID-19 admissions and carried a mortality rate of 17.7%. Profound bradycardia occurred in 13% of patients and carried a mortality rate of 25.5%. They reported an odds ratio of 6.59 (95% CI, 2.83-15.36) for mortality in those with absolute bradycardia compared to individuals with a normal HR response.

Complete AV block, though quite rare, was reported by Li et al. to occur at a rate of 1.5% in their cohort of patients from China. They found that any form of conduction block occurred at an overall rate of 11.9%, with first-degree
It is not clear whether the occurrence of profound bradycardia and high-degree AV block is potentially reversible when a patient recovers from their acute infection. Dysautonomia in particular has been documented quite frequently in the post-infectious period and carries its own long-term management implications. The ALBACOVID registry in Spain retrospectively obtained neurologic data from COVID-19 admissions and found that dysautonomia occurred at a rate of 2.5%. Shouman et al. evaluated patients with COVID-19 infection who had been referred for autonomic testing at the Mayo Clinic and found that 22% of them fulfilled criteria for postural orthostatic tachycardia syndrome (POTS). Only one patient in their review was diagnosed with inappropriate sinus tachycardia (IST). In a cohort of 200 patients with symptoms persisting 3 months after COVID-19 infection, Llach et al. found that IST or POTS criteria were met in 17% of patients, with 26 cases of IST and 8 cases of POTS. These patients had no structural heart disease identified on echocardiography but had significantly diminished exercise capacity on 6-minute walk test and altered heart rate variability on 24-hour Holter monitoring.

Mechanistically, it is unclear why dysautonomia persists into the convalescent period of COVID-19 infection; however, similar to other viral syndromes, the cause is theorized to be a post-infectious autoimmune phenomenon. As with other patients with dysautonomias, these conditions can be managed with both pharmacologic and nonpharmacologic measures. Nonpharmacologic measures, particularly for POTS, include compression stockings, increased salt intake, and regular exercise to improve physical conditioning. Pharmacologic measures for POTS—depending on the primary etiology—can include mineralocorticoids, alpha agonists, beta blockers, or ivabradine. Similarly, IST can be managed with either beta blockers or ivabradine, although ivabradine use is off label for both IST and POTS and not FDA approved for these conditions.

**CONCLUSIONS**

COVID-19 continues to have a global impact both during and after infection. As our understanding of this disease evolves, we will hopefully have better insights into its unique pathophysiology and arrhythmic complications. Atrial fibrillation has been documented in multiple studies as the most common pathologic arrhythmia in COVID-19 infection and has been shown to be a poor prognostic marker, associated with increased risk for mortality especially in new-onset cases. Bradyarrhythmia also tends to be a common arrhythmia in the acute phase and also is associated with poor prognosis. As we move into the post-COVID period, more data is needed on the long-term arrhythmic effects of the disease to gain a better understanding of how to manage patients in the

**MANAGEMENT OF CARDIAC ARRHYTHMIA DURING COVID INFECTION**

The medical management of arrhythmias during the acute COVID-19 infectious period has not deviated much from standard practice. For atrial arrhythmias, rate and rhythm control strategies have remained the mainstay of treatment. However, the use of beta blockers for rate control has been a common concern due to the potential for bronchospasm in the active phase of COVID-19 infection; thus, many have used nondihydropyridine calcium channel blockers such as diltiazem as an alternative to avoid this potential side effect. Rhythm control with amiodarone is still quite common, reported by Berman et al. as 29% of COVID-19 patients referred for electrophysiology consultation at Columbia University. For ventricular arrhythmias, specific QTc and electrolyte monitoring is required during the acute phase of COVID-19 infection, especially if proarrhythmicogenic drugs are used. The incidence of ventricular arrhythmias has primarily been associated with critically ill patients in the setting of ventilation, permissive hypercapnia, and electrolyte imbalances. Thus, efforts would best be focused towards minimizing the impact of these factors. There have been some reported cases of VT storm where substrate-based VT catheter ablation was efficacious. This may prove to be a viable alternative in those who may not be suited for antiarrhythmics.

In bradyarrhythmias, permissive hyperthermia to avoid hypothermia can be useful in minimizing sinus bradycardia. The use of inotropic agents such as dopamine or dobutamine can additionally be used for supportive care. Also, temporary pacemakers have been used when all other measures fail. It is not clear whether the occurrence of profound bradycardia and high-degree AV block is potentially reversible when a patient recovers from their acute infection.

**ARRHYTHMIA IN THE COVID-19 CONVALESCENT PERIOD**

There is an ongoing effort to better understand post COVID-19 condition—that is, the long-term effects of acute infection in COVID-19 patients. Many arrhythmias have been anecdotally noted in this period, including ventricular arrhythmias such as PVCs and ventricular tachycardia, although large data sets on this are still quite limited.
convalescent period. Additionally, further studies will be needed to monitor for long-term arrhythmias associated with new therapies.

**KEY POINTS**

- The most common arrhythmias in the acute infectious period of COVID-19 are sinus tachycardia (nonpathologic) and atrial fibrillation (pathologic).
- Atrial fibrillation is a poor prognostic marker and has been associated with higher mortality, especially in new-onset cases.
- Malignant arrhythmias such as ventricular tachycardia, ventricular fibrillation, and atrioventricular block are rare.
- Special interdisciplinary care is needed to balance the medical management of these patients to minimize iatrogenic contributions to arrhythmias.
- Inappropriate sinus tachycardia and postural orthostatic tachycardia syndrome seem to be common in the convalescent period of COVID-19 infection as a result of post-infectious dysautonomia.

**COMPETING INTERESTS**

The authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.

**AUTHOR AFFILIATIONS**

Summit Pandat, MD  
Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas, US

Zhihao Zhu, MD  
Houston Methodist Hospital, Houston, Texas, US

Stephanie Fuentes-Rojas, MD  
Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas, US

Paul Schurmann, MD  
Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas, US

**REFERENCES**

1. Azevedo RB, Botelho BG, Hollanda JVG, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021 Jan;35(1):4-11. doi: 10.1038/s41371-020-0387-4

2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585

3. Griffin DO, Brennan-Rieder D, Ngo B, et al. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021 Feb 8;23(1):40-47. doi: 10.24875/AIDSRev.2020001261

4. Atri D, Siddiqi HK, Lang JP, et al. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic Transl Sci. 2020 Apr 10;5(5):518-536. doi: 10.1016/j.jatcbs.2020.04.002

5. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017 Jun 7;38(22):1717-1727. doi: 10.1093/eurheartj/ehw208

6. Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019 Jan;19(1):63-64. doi: 10.1038/s41577-018-0098-z

7. Clark RE, Christlieb I, Sanmarco M, Diaz-Perez R, Damann JF, Zipser ME. Relationship of hypoxia to arrhythmia and cardiac conduction hemorrhage. Circulation. 1963 Apr 1;27:742-747. doi: 10.1161/01.CIR.27.4.742

8. Macdonald WA, Hool LC. The effect of acute hypoxia on excitability in the heart and the L-type calcium channel as a therapeutic target. Curr Drug Discov Technol. 2008 Dec;5(4):302-11. doi: 10.2174/157016308786733546

9. Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, Arrhythmic Risk, and Inflammation: Mind the Gap! Circulation. 2020 Jul 7;142(1):7-9. doi: 10.1161/CIRCULATIONAHA.120.047293

10. Kolettis TM. Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment. Curr Opin Pharmacol. 2013 Apr;13(2):210-7. doi: 10.1016/j.coph.2013.01.001

11. Gemel J, Su Z, Gileles-Hillel A, Khalyfa A, Gozal D, Beyer EC. Intermittent hypoxia causes NOX2-dependent remodeling of atrial connexins. BMC Cell Biol. 2017 Jan 17;18(Suppl 1):7. doi: 10.1186/s12860-016-0117-5

12. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):567-571. doi: 10.3760/cma.j.cn112148-20200225-00123

13. Babapoor-Farrokhran S, Gill D, Walker J, Rosekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020 Jul 15;253:117723. doi: 10.1016/j.lfs.2020.117723
14. Peretto G, Sala S, Rizzo S, et al. Arrhythmias in myocarditis: State of the art. Heart Rhythm. 2019 May;16(5):793-801. doi: 10.1016/j.hrthm.2018.11.024

15. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834

16. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024

17. Dherange P, Long J, Qian P, et al. Arrhythmias and COVID-19: A Review. JACC Clin Electrophysiol. 2020 Sep;6(9):1193-1204. doi: 10.1016/j.jcledp.2020.08.002

18. Amaratunga EA, Corwin DS, Moran L, Snyder R. Bradycardia in Patients With COVID-19: A Calm Before the Storm? Cureus. 2020 Jun 13;12(6):e8599. doi: 10.7759/cureus.8599

19. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949

20. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19. N Engl J Med. 2020 Nov 19;383(21):e119. doi: 10.1056/NEJMoa2000202

21. Chang D, Saleh M, Gabriels J, et al. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin. J Am Coll Cardiol. 2020 Jun 16;75(23):2992-2993. doi: 10.1016/j.jacc.2020.04.032

22. Mozzanti A, Briani M, Kukavica D, et al. Association of Hydroxychloroquine With QT Interval in Patients With COVID-19. Circulation. 2020 Aug 4;142(5):513-515. doi: 10.1161/CIRCULATIONAHA.120.048476

23. Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai MC. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm. 2020 Sep;17(9):1472-1479. doi: 10.1016/j.hrthm.2020.05.008

24. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59(3):252-6. doi: 10.1136/thorax.2003.012658

25. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):555-9. doi: 10.3851/IMP3002

26. Chaubey SK, Sinha AK, Phillips E, Russell DB, Falhammar H. Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection. Sex Health. 2009 Sep;6(3):254-7. doi: 10.1071/SH09005

27. Beys A, Martin N, Hermida A, Abou-Abad O, Mahjoub Y. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia. Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008798. doi: 10.1161/CIRCEP.120.008798

28. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282

29. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764

30. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349

31. Gubitosa JC, Kakar P, Gerula C, et al. Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review. JACC Case Rep. 2020 Nov 5;3(9):791.e5-791.e8. doi: 10.1016/j.jaccrep.2020.02.013

32. Gupta AK, Parker BM, Priyadarshi V, Parker J. Cardiac Adverse Events With Remdesivir in COVID-19 Infection. Cureus. 2020 Oct 24;12(10):e11132. doi: 10.7759/cureus.11132

33. Toufchia A, Bagheri H, Carrié D, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect. 2021 Feb 27;27(5):791. e5-791.e8. doi: 10.1016/j.cmi.2021.02.013

34. Gupta S, Wang W, Hayek SS, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252

35. Salama C, Han J, You L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340

36. Lazzorini PE, Acampa M, Caperchi PL, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res (Hoboken). 2015 Mar;67(3):332-9. doi: 10.1002/acr.22455

37. Horby P, Lim WS, Emberson JR, et al. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436

38. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006 May 8;166(9):1016-20. doi: 10.1001/archinte.166.9.1016
40. Liu Q, Kong AL, Chen R, et al. Propofol and arrhythmias: two sides of the coin. Acta Pharmacol Sin. 2011 Jun;32(6):817-23. doi: 10.1038/aps.2011.42

41. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012 Mar 21;307(11):1151-60. doi: 10.1001/jama.2012.304

42. Kako H, Krishna SG, Sebastian R, Smith K, Tobias JD. Effect of dexmedetomidine on the QT interval in pediatric patients undergoing general anesthesia. J Anesth. 2015 Dec;29(6):862-7. doi: 10.1007/s00540-015-2056-2

43. Zhou WJ, Liu M, Fan XP. Differences in efficacy and safety of midazolam vs. dexmedetomidine in critically ill patients: A meta-analysis of randomized controlled trial. Exp Ther Med. 2021 Feb;21(2):156. doi: 10.3892/etm.2020.9297

44. Zareini B, Rojan D, El-Sheikh M, et al. Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study. Heart Rhythm. 2021 Mar 23;2(3):304-308. doi: 10.1016/j.hrthm.2021.03.008

45. Cho JH, Namazi A, Shelton R, et al. Cardiac arrhythmias in hospitalized patients with COVID-19: A prospective observational study in the western United States. PLoS One. 2020 Dec 28;15(12):e0244533. doi: 10.1371/journal.pone.0244533

46. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and cardiac arrhythmias. Heart Rhythm. 2020 Sep;17(9):1439-1444. doi: 10.1016/j.hrthm.2020.06.016

47. Musikantow DR, Turagam MK, Sartori S, et al. Atrial Fibrillation in Patients Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and Comparison to Influenza. JACC Clin Electrophysiol. 2021 Sep;7(9):1120-1130. doi: 10.1016/j.jcep.2021.02.009

48. Ip RJ, Ali A, Baloch ZQ, et al. Atrial Fibrillation as a Predictor of Mortality in High Risk COVID-19 Patients: A Multicentre Study of 171 Patients. Heart Lung Circ. 2021 Aug;30(8):1151-1156. doi: 10.1016/j.hlc.2021.02.010

49. Mountantonakis SE, Saleh M, Fishbein J, et al. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021 Apr;18(4):501-507. doi: 10.1016/j.hrthm.2021.01.018

50. Yarmohammadi H, Morrow JP, Dizon J, et al. Frequency of Atrial Arrhythmia in Hospitalized Patients With COVID-19. Am J Cardiol. 2021 May 15;147:52-57. doi: 10.1016/j.ajcard.2021.01.039

51. Abrams MP, Coromilas EJ, Wan EY, Rubin GA, Garan H, Dizon JM. Malignant ventricular arrhythmias in patients with severe acute respiratory distress syndrome due to COVID-19 without significant structural heart disease. HeartRhythm Case Rep. 2020 Nov;6(11):858-862. doi: 10.1016/j.hrcr.2020.08.017

52. Shao F, Xu S, Ma X, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020 Jun;151:18-23. doi: 10.1016/j.resuscitation.2020.04.005

53. Chinitz JS, Goyal R, Hardining M, et al. Bradycardiac in patients with COVID-19: Marker of poor prognosis? Pacing Clin Electrophysiol. 2020 Oct;43(10):1199-1204. doi: 10.1111/pace.14042

54. Kumar S, Arcuri C, Choudhuri S, et al. A novel study on SARS-COV-2 virus associated bradycardia as a predictor of mortality-retrospective multicenter analysis. Clin Cardiol. 2021 Jun;44(6):857-862. doi: 10.1002/clc.23622

55. Li Y, Liu T, Tse G, et al. Electrocardiographic characteristics in patients with coronavirus infection: A single-center observational study. Ann Noninvasive Electrocardiol. 2020 Sep;25(6):e12805. doi: 10.1111/anec.12805

56. Berman JP, Abrams MP, Kushnir A, et al. Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. Indian Pacing Electrophysiol J. Nov-Dec 2020;20(6):250-256. doi: 10.1016/j.ipej.2020.08.006

57. Desai AD, Boursiquot BC, Melki L, Wan EY. Management of Arrhythmias Associated with COVID-19. Curr Cardiol Rep. 2020 Nov 24;23(1):2. doi: 10.1007/s10286-020-01434-7

58. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020 Aug 25;95(8):e1060-e1070. doi: 10.1212/ WNL.0000000000009937

59. Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Curr Auton Res. 2021 Jun;31(3):385-394. doi: 10.1007/s10286-021-00803-8

60. Arano Llach J, Victor Bazan VBG, Gemma Llados GLL, et al. Inappropriate sinus tachycardia in post-covid-19 Syndrome. Europace. 2021 May;23(Suppl 3):e16116.114. doi: 10.1093/europace/eub116.114
